If Stanton's pps target is post-EPP aproval, then he's talking about a 56% return on investment henceforward.
For most investments, a 56% return is outstanding. But, when you're talking about the risks of regulatory approval decisions (risky for ANY pharma / biotech stock), a 56% return on a first in-class drug is not as great of a risk/ reward profile to me as it would appear at first glance.
For other biotechs that I have seen, there is much bigger upside potential for post-approval.
Having said that, I feel this drug will be approved (I've always said that) and that there is less risk than most other first in-class drug applications out there.
Also, Stanton's call is not gospel.
But there are biotechs out there that perform better than 56% 6-9 months outside of approval.
Remember, we're competiting with other pharma / biotech investments given investors in this space are looking for the best investment opportunities out there for their money.
- Forums
- ASX - By Stock
- CUV
- 56 percent return on cuv?
56 percent return on cuv?
Featured News
Add CUV (ASX) to my watchlist
|
|||||
Last
$13.96 |
Change
-0.200(1.41%) |
Mkt cap ! $699.0M |
Open | High | Low | Value | Volume |
$14.20 | $14.24 | $13.88 | $631.9K | 44.90K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 416 | $13.96 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.04 | 192 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 416 | 13.960 |
1 | 1435 | 13.920 |
2 | 262 | 13.880 |
1 | 192 | 13.860 |
1 | 192 | 13.830 |
Price($) | Vol. | No. |
---|---|---|
14.040 | 192 | 1 |
14.060 | 192 | 1 |
14.070 | 200 | 1 |
14.090 | 192 | 1 |
14.100 | 600 | 1 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online